Literature DB >> 33982052

From secondary to tertiary mitral regurgitation: the paradigm shifts, but uncertainties remain.

Antonio Landi1, Francesco Fulvio Faletra1, Anna Giulia Pavon2, Giovanni Pedrazzini1,3, Marco Valgimigli1,4.   

Abstract

Secondary mitral regurgitation (MR) is the most common and undertreated form of MR, whose contribution to poor prognosis and indications to correction remains under discussion. MR has been characterized into 'proportionate' or 'disproportionate', based on left ventricle (LV) and regurgitant volumes, whereas 'tertiary' MR identifies conditions, in which regurgitation is pathologic per se and actively contributes to LV dysfunction. Echocardiographic and anatomo-pathological studies revealed that secondary MR prompts subtle leaflet maladaptive changes, actively contributing to the dynamic progression of secondary MR. We critically discuss the paradigm shift from secondary to tertiary MR and question the notion that MV leaflets play a passive role in secondary MR. We also review the role of standard transthoracic echocardiography for appraising and quantifying maladaptive MV leaflet changes and LV volumes and call for a more sophisticated and comprehensive imaging framework for classifying MR in future interventional studies. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  edge-to-edge mitral valve repair; mitral valve leaflets; proportionate mitral valve regurgitation; secondary mitral regurgitation

Mesh:

Year:  2021        PMID: 33982052     DOI: 10.1093/ehjci/jeab080

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  1 in total

1.  Three-Dimensional Echocardiography Based on Automation and Machine Learning Principles and the Renaissance of Cardiac Morphometry.

Authors:  Andrea Barbieri; Mauro Pepi
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.